期刊
HEALTH AFFAIRS
卷 25, 期 5, 页码 1371-1377出版社
PROJECT HOPE
DOI: 10.1377/hlthaff.25.5.1371
关键词
-
资金
- AHRQ HHS [1 R01 HS011326-01A2] Funding Source: Medline
- NHLBI NIH HHS [1 R01 HL077841-01] Funding Source: Medline
- AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS011326] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077841] Funding Source: NIH RePORTER
Concern about the potential pernicious effect of direct-to-consumer(DTC) drug advertising on physicians' prescribing patterns was heightened with the 2004 withdrawal of Vioxx, a heavily advertised treatment for osteoarthritis. We examine how DTC advertising has affected physicians' prescribing behavior for osteoarthritis patients. We analyzed monthly clinical information on fifty-seven primary care practices during 2000-2002, matched to monthly brand-specific advertising data for local and network television. DTC advertising of Vioxx and Celebrex increased the number of osteoarthritis patients seen by physicians each month. DTC advertising of Vioxx increased the likelihood that patients received both Vioxx and Celebrex, but Celebrex ads only affected Vioxx use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据